Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.235 AUD | +1.23% | -2.57% | -24.62% |
03-06 | Morgan Stanley Adjusts Healius’ Price Target to AU$1 From AU$1.30, Keeps at Underweight | MT |
03-05 | Australia shares inch lower as miners weigh; GDP data in focus | RE |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Most analysts recommend that the stock should be sold or reduced.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-24.62% | 566M | B- | ||
-16.46% | 8.25B | B+ | ||
+40.93% | 3.58B | C+ | ||
-35.59% | 2.46B | B- | ||
-7.88% | 2.46B | - | ||
-8.95% | 2.38B | B- | ||
-5.93% | 1.81B | C- | ||
-18.96% | 1.55B | A- | ||
-38.35% | 1.21B | C+ | ||
+6.91% | 1.11B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HLS Stock
- Ratings Healius Limited